Since previous clinical evidence for renal effects of DPP-4 inhibitors has mainly emerged from patient populations at earlier stages of kidney disease, CARMELINA® will answer an important question whether DPP-4 inhibition with linagliptin may have the potential to alter renal disease progression at more advanced stages of the renal continuum. This evidence concerns the gene DPP4 and kidney disorder.